unfractionated heparin + eptifibatide

**unfractionated heparin + eptifibatide** is a combination of two intravenous antithrombotic agents used primarily in the management of acute coronary syndromes (ACS), especially non-ST-segment elevation ACS and during percutaneous coronary intervention (PCI). Unfractionated heparin is a glycosaminoglycan anticoagulant that enhances the inhibition of thrombin and factor Xa by antithrombin III, reducing the formation of fibrin clots. Eptifibatide is a synthetic cyclic heptapeptide belonging to the glycoprotein IIb/IIIa inhibitor class ("arginine-glycine-aspartate-mimetics"), which reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to the GP IIb/IIIa receptor on platelets[2][4][8][6]. The combination targets complementary mechanisms of thrombus formation: heparin targets the coagulation cascade, while eptifibatide inhibits platelet aggregation, thereby synergistically reducing the risk of ischemic adverse effects in ACS[1]. This therapy is intended for use in hospitalized patients, often alongside aspirin. Developers and manufacturers for each drug are listed separately below.

Other names

unfractionated heparin + eptifibatide